DBV CSO stepping down; plus moves at Idera, Ultimovacs, Omniome, Humacyte and Aelis Farma

Food allergy company  DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) announced that Hugh Sampson is stepping down from his role as CSO, effective Dec. 1. Sampson will remain as scientific adviser to the CEO and chairman of DBV’s scientific advisory board.

Daniel Soland will join cancer and rare disease company Idera Pharmaceuticals Inc. (NASDAQ:IDRA) on Jan. 4, 2021 as SVP and COO. He was CEO of uniQure N.V. (NASDAQ:QURE). Idera also announced that R. Clayton Fletcher, SVP of business development and strategic planning, will retire at year-end and remain a consultant to the company...